Immunome Inc. 4

Immunome Inc. President and CEO Clay B. Siegall received 180,000 RSUs and options on 360,000 shares of common stock at $22.01 per share as part of an equity compensation grant.

On July 23, 2026, Immunome Inc. President and CEO Clay B. Siegall received an equity compensation package consisting of 180,000 restricted stock units (RSUs) and a stock option grant for 360,000 shares at an exercise price of $22.01 per share. The RSUs, representing 180,000 shares of common stock, vest annually in four equal installments of 25% on each anniversary of the grant date, contingent on continued service. The stock options, covering 360,000 shares of common stock, vest 25% on July 23, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, and are exercisable until July 22, 2036. Following these awards, Siegall beneficially owned 870,704 shares of Immunome common stock. Using the $22.01 option exercise price as a proxy for the stock price, the RSU grant is valued at approximately $3.96 million, the option grant has a notional underlying value of about $7.92 million, and his post-transaction common stock holdings are worth roughly $19.2 million, indicating a substantial, primarily incentive-based alignment with shareholders.

Filing Facts

CIK

1472012

Ticker

IMNM

Form

4

Source Type

fda

Accession

0001167496-26-000005

Alert Tier

7